Salvage liver transplantation (slt) and repeated resection (rr) are effective treatments for recurrent hepatocellular carcinoma (Hcc), and comparisons of the oncological outcomes between these 2 modalities were scarce. consecutive patients admitted for either slt or rr for recurrent Hcc were recruited. all patients in the present series received either prior hepatectomy, ablative therapy, or both before rr or slt. Patient demographic, perioperative, and outcome data were analyzed. a survival analysis was performed after propensity score matching. there were 277 eligible patients recruited, and 67 and 210 of them underwent slt and rr, respectively. Significant differences in preoperative hemoglobin, albumin, Model of end-Stage liver Disease (MelD) score, and tumor number were found between the slt and rr groups. after 1:3 propensity score matching, there were 36 slt and 108 rr patients for comparison. the median age, MelD, alpha fetoprotein, and tumor size and number of the matched population were 57 years, 7.5, 16 ng/ml, 2.5 cm, and 1, respectively. there was no difference in the hospital mortality and complication rate (clavien iiia or above) between the groups. the recurrence rate after rr was significantly higher than for the patients who received slt (72.2% versus 27.8%; P < 0.001). Following rr, 3 patients received liver transplantation for further recurrence, and 54.6% of the patients developed nontransplantable recurrence. the 5-year disease-free survival (DFS) and overall survival (OS) were both superior in the slt group (DFS, 71.6% versus 32.8%, P < 0.001; OS, 72.8% versus 48.3%, P = 0.007). in conclusion, slt is superior to rr for treatment of recurrent Hcc in terms of DFS and OS. the high rate of nontransplantable recurrence after reresection underscores the importance of timely slt. Hepatocellular carcinoma (HCC) is the fifth most common cancer and third most common cause of cancer-related mortality in the world, (1) leading to over a million deaths each year. (2) Liver resection and tumor ablative therapy are 2 popular and effective first-line treatments for HCC. Because most HCC develops in a cirrhotic liver, together with its propensity for portal vein invasion, intrahepatic recurrence is frequent. The reported recurrence rates after resection and ablation were on the order of 60% and 80%, respectively. (3-6) When intrahepatic recurrence develops, repeated resection (RR) and salvage liver transplantation (sLT) are the 2 viable treatment options. A number of retrospective cohorts reported satisfactory survival of 67%-83% with RR, (7) (8) (9) whereas the reported 5-year disease-free survival (DFS) and overall survival (OS) rates after sLT were both approximately 50%-70%. (10) (11) (12) (13) Despite the survival outcomes of RR and sLT, the strategy appeared similar, and direct comparison between RR and sLT has been scarce. (14) In addition, a fundamental difference in demographics, liver function, and tumor characteristic often exist between patients who received RR and transplantation. This heterogeneity potentially leads to biased analysis and deduction. A propensity score matched analysis is the best way to alleviate this
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shortcoming especially because a randomized controlled trial is not practically feasible in this setting. However, propensity score matched studies comparing RR versus sLT were limited in the literature. This study serves to compare the oncological outcomes of these 2 treatment modalities for recurrent HCC.
Patients and Methods

pATienT BACKGroUnD AnD reCrUiTMenT
Consecutive patients who underwent RR or sLT for recurrent HCC from 1996 to 2016 in Queen Mary Hospital, The University of Hong Kong, were extracted from a prospectively maintained database. Approval from the institutional review board was not required for the retrospective study. Adult patients with a history of HCC that was previously treated by either radiofrequency ablation (RFA) or hepatectomy were eligible. Patients with incomplete resection (macroscopic or microscopic positive margin), pathology other than HCC, and presence of extrahepatic disease were excluded. Demographic, preoperative investigations, perioperative, and survival data were retrieved for analysis. Categorical variables and continuous variables were analyzed by chi-square test and MannWhitney U test, respectively. To reduce the confounding effect from the heterogeneities between RR and sLT groups, propensity score matching was performed using the nearest neighbor matching method. (15) Independent factors associated with survival were identified with multivariate analysis using the Cox regression model. Survival analyses were done with the Kaplan-Meier method and were compared with the log-rank test. All statistical analyses were processed with SPSS, version 24.0 (IBM, Armonk, NY).
repeATeD reSeCTion GroUp
Diagnosis of recurrent HCC was made by contrasted cross-sectional imaging, ie, computed tomography (CT) or magnetic resonance imaging (MRI), showing lesions with typical arterial enhancement and portal venous washout. (16) Elevation of alpha fetoprotein (AFP) was not a prerequisite for the diagnosis of HCC recurrence. RR was offered if complete resection of the tumor with a good margin was deemed possible. Patients were considered suitable for RR if they had Child A or early B liver cirrhosis, indocyanine green retention <20% in 15 minutes, (17, 18) and if the ratio of future liver remnant to estimated standard liver volume after RR was more than 30%. (19) The surgical technique of hepatectomy has been described elsewhere. (20) (21) (22) In brief, after perihepatic adhesions were taken down, intraoperative ultrasound was performed to outline the tumor and for vascular mapping. For a major hepatectomy, vascular inflows (hepatic artery and portal vein) were individually controlled and ligated. Parenchymal transection continued with a cavitron ultrasonic surgical aspirator along the line of demarcation. The hepatic vein was divided with a vascular stapler. Postoperatively, patients were followed up at the clinic at 1 month, 3 months, and then every 6 months after the operation. Routine blood tests including AFP were checked at each follow-up. Surveillance-contrasted imaging (CT or MRI) was performed 3 months postoperatively, followed by a 6-monthly imaging protocol after the operation.
SALvAGe Liver TrAnSpLAnTATion GroUp
Patients with recurrent HCC were considered potential candidates for deceased donor liver transplantation if: 1. HCC in both the previous and latest episode were within University of California, San Francisco (UCSF) criteria. (23) 2. The patient was physically and psychologically fit for liver transplantation (LT).
Upon completion of the transplant workup, (24) patients were put on the transplant waiting list after discussion in a board meeting. Patients with HCC of United Network for Organ Sharing stage II for more than 6 months would be given a bonus Model of EndStage Liver Disease (MELD) score, starting from 18 points with an additional 2 points granted every 3 months afterward. (18, 25) The MELD score was frozen without penalty if HCC progressed to stage III or beyond. Patients were delisted if HCC progressed to beyond UCSF criteria.
Liver-directed therapy as a bridge to LT was given to every listed patient whenever possible. There were 3 modalities of bridging therapy available at our center, namely, transarterial chemoembolization (TACE), high-intensity focused ultrasound (HIFU), and stereotactic body radiotherapy (SBRT). The decision on which type of bridging therapy was offered was made on an individual basis. For example, TACE was the most commonly used bridging therapy for patients with relatively preserved liver function (ie, Child B or below); SBRT is good for a deep-seated, sizeable tumor or for patients with portal vein thrombosis; and HIFU was feasible even in patients with poor liver function. (26, 27) For sLT using a living donor graft, bridging therapy was not required. Patients with HCC size and number slightly beyond UCSF criteria could still be considered eligible for LDLT provided that there was no extrahepatic disease, and that major vascular and recurrence risks were accepted by all parties. This study did not involve the use of organs from executed prisoners. For immunosuppressive protocol, it was the same as per transplantation for non-HCC patients. In general, hydrocortisone and basiliximab were given intraoperatively and on postoperative days 1 and 4, respectively). Mycophenolate mofetil and tacrolimus were started on postoperative day 1. Monoimmunosuppression using tacrolimus was maintained lifelong. Tacrolimus would be switched to mammalian target of rapamycin inhibitor subsequently in case of intolerance or HCC recurrence.
results
BASeLine CHArACTeriSTiCS oF THe WHoLe STUDY popULATion
There were 277 consecutive patients eligible for the study who were retrieved from the database. The median follow-up time was 43 months. The median age was 57 years old, and male (77.3%) was the predominating sex. A majority of the patients were hepatitis B carriers, whereas hepatitis C antibody was found in 9.3% of the patients. The median Child score, MELD score, and AFP level was 5 (range, 5-15), 7.5 (range, , and 17 (range, 1-1.3 × 10 5 ) ng/mL, respectively. The median tumor size was 2.5 cm (range, 0.3-10.6 cm), and more than over half of the patients had solitary HCC recurrence (range, 1-9 nodules). There were 68 patients with recurrent HCC who were beyond UCSF criteria. Within the study period, RR and sLT were performed for 210 and 67 patients, respectively. The average listing time for the whole sLT group was 171 days (median waiting time for a deceased and living liver graft was 298 and 24 days, respectively). The median disease-free period between the previous and the last HCC treatment (lapse time from last HCC treatment) was 27 months (range, 1-322 months). Lymphovascular invasion (LVI) was found in 42.5% of the surgical specimens. Well or moderate tumor differentiation was identified in 73.3% of the tumor pathology. The median DFS and OS was 30.7 and 107.2 months, respectively, for the whole population (Table 1) .
propenSiTY SCore MATCHinG AnD poSToperATive oUTCoMeS
Factors that demonstrated significant difference between the sLT and RR groups are shown in Table 2 , namely, hemoglobin, bilirubin, albumin, MELD score, number of HCC nodules, and UCSF criteria. After propensity score matching, there were 144 patients (36 sLT and 108 RR patients) available for survival analyses (Table 2 ). There was no significant difference in major complication rates (16% versus 8.3%; P = 0.21) and hospital mortality rates (0% versus 1.9%; P > 0.99). However, patients in the sLT group had significantly more blood loss (1950 versus 470 mL; P < 0.001), longer operation time (692 versus 282 minutes; P < 0.001), and longer hospital length of stay (13 versus 7 days; P = 0.003) when compared with the patients in the RR group. For this matched population, HCC recurrence developed in 88 patients, resulting in a recurrence rate of 27.8% and 72.2% in the sLT and RR groups, respectively.
Curative RR was achieved in 30 (27.8%) patients, and 37 (34.3%) patients recurred with extrahepatic diseases. Among the 41 patients who developed intrahepatic recurrence after RR, 3 patients received a LT, and 16 received further resection or ablation. The majority of the patients were not transplant candidates once further recurrence occurred (Fig. 1) .
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UnivAriATe AnD MULTivAriATe AnALYSiS For SUrvivALS
In the matched population, preoperative AFP level (P = 0.042), time lapse from last HCC treatment (P = 0.014), and sLT (P < 0.001) were found to be associated with DFS. After multivariate analysis, only time lapse from last HCC treatment (odds ratio [OR] 0.99; 95% confidence interval [CI], 0.98-0.998; P = 0.02) and sLT (OR, 0.23; 95% CI, 0.12-0.47; P < 0.001) were independent factors for DFS (Table 3) . Patients who received sLT for recurrence had significantly better 5-year DFS (71.6% versus 32.8%; log-rank P = 0.001; Fig. 2 ). Concerning OS, AFP (P < 0.001), UCSF criteria (P = 0.047), and sLT (P = 0.009) were found to be associated with OS. After multivariate analysis, only UCSF criteria (OR, 1.83; 95% CI, 1.09-3.08; P = 0.02) and sLT (OR, 0.37; 95% CI, 0.18-0.76; P = 0.01) were identified as independent factors (Table 4) . Patients in the sLT group had significantly better 5-year OS (72.8% versus 48.3%; log-rank P = 0.007; Fig. 3 ). 
Discussion
This propensity score matched analysis that was composed of 144 patients with recurrent HCC suggested that sLT is a superior treatment modality, leading to a roughly 40% and 20% improvement in 5-year DFS and OS, respectively, when compared with RR. Short time to recurrence following curative resection for HCC had been shown to be an associated factor for poor oncological outcomes (28) (29) (30) ; this association was again demonstrated in the multivariate analysis in our current series suggesting that the time to recurrence is a reflection of tumor virulence.
Theoretically, LT allows for the removal of the tumor with the largest possible resection margin and replaces it with a new liver that is free of cirrhosis. It has been shown that LT provides oncologically better outcomes when compared with liver resection for HCC patients. In contrast, the oncological benefits of LT for recurrent HCC were less well-defined. Generally speaking, recurrent HCC possesses more aggressive tumor biology, and immunosuppressive therapy associated with sLT might lead to early recurrence and even dissemination. This partially explains why some series reported an inferior recurrence-free survival in sLT in comparison to primary LT for HCC. (31) Whether this inferior oncological outcome in sLT would still be better than RR for recurrent HCC remains an area of research because studies comparing these 2 treatment modalities are scarce. Zhang et al. performed an unmatched comparative analysis between 36 sLT and 116 RR/repeated ablation. They found that patients Original article | 1067 who received sLT had a superior DFS. However, their patients in the RR/ablation group had significantly earlier recurrence, which might imply poorer tumor biology in the resection group and which might represent a confounding factor. (32) Lim et al. (33) recently reported an intention-to-treat analysis, in which they included 99 patients who were diagnosed with recurrent HCC (18 received sLT and 81 received RR). They found that sLT is associated with superior DFS but not OS. These findings partially concurred with those of our current series. Because further resection became less likely after prior hepatectomies, management for the third time of HCC recurrence was chiefly palliative, and this explained the worse OS in our RR group. In the management of patients with recurrent HCC, the decision on whether to go for sLT or RR is partially determined by the average graft waiting time. Because of the scarcity of deceased organs in our locality, (34) patients with recurrent HCC often need to wait for a considerably long period before they can be given a liver graft. In our current series, most patients waited for more than 9 months for a deceased graft. In addition to the issue of long waiting times, prompt and effective treatment (ie, LT) for recurrent HCC is of paramount importance because recurrent tumors are expected to be more virulent with faster disease progression. In order to improve the chance of transplantation, bridging therapy by means of SBRT, TACE, or HIFU should be offered whenever possible in order to slow down the tumor progression. (35) Second, a bonus MELD score should be considered in eligible patients to reduce dropout rate. (25) Last but not least, the availability of a living donor graft should always be explored. However, the lack of waiting time (ie, median waiting time of 24 days in our series) in LDLT means negating the "test-of-time," which theoretically allows aggressive HCC to reveal itself. LDLT patients with poor tumor biology might be transplanted as such with potentially higher recurrence rates. Nonetheless, LDLT often represents the last chance of a cure, especially for patients with low MELD scores or tumors beyond the UCSF criteria. Development of nontransplantable recurrence had been the Achilles' heel of sLT policy. Many series reported a nontransplantability rate of approximately 30% after the initial resection. This concern seems to be even more valid in the context of choosing between RR and sLT for recurrent HCC patients. In our study, nontransplantable recurrence developed in 55% of the patients who received RR, which implies that the chance of a successful LT diminished as it was postponed to the next recurrence episode.
There were some limitations for the current study. First, the retrospective and single-center design was inherently susceptible to missing data and selection bias. Second, because of missing data and the retrospective nature of the study design, an intention-totreat OS analysis could not be performed. In addition, complete matching of all parameters between the RR and sLT groups was not possible due to the limited population size and fundamental differences of the patients between the groups. Nonetheless, the current study compared the survival outcomes of sLT versus RR in a propensity score matched population which should represent a reasonably strong evidence in the absence of a randomized controlled trial to address the concerned clinical question.
